comprehensive -WSS

comprehensive

author：explore 2025-09-06 02:04:11 - browse：12

Is biotech back from its downturn? Can Nvidia solve biology? And is it wise to do a deal on a party bus?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recording from the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech at the outset of 2024. We also talk about the latest twist in the Sarepta Therapeutics saga, a ubiquitous dealmaker, and life on the party circuit.

For more on what we cover, here’s the news on Sarepta; here’s more on Nvidia; here’s the story on Centerview; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Alkermes shareholders re
Next article： What is microchimerism and how does it affect maternal health?

knowledge

explore

WSS

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

After Sarepta trial failure, Duchenne families brace for more debate

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Humans aren't the only ones with an imagination. Rats have it too

leisure time

comprehensive

explore

Supreme Court strikes down use of affirmative action

What causes an itch? Researchers may have solved the mystery

Wildfire smoke exposes gaps in outdoor worker protections

Leukemia patients are helped by Syndax's new type of therapy

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Guidelines to prevent youth baseball injuries need more muscle

Chemotherapy shortages won’t get better under Biden’s latest plan

Supreme Court strikes down use of affirmative action

SCOTUS to consider access to abortion pill mifepristone

explore

Roche to buy Carmot Therapeutics, developer of obesity drugs

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Chemotherapy shortages won’t get better under Biden’s latest plan

FDA needs staff influx to meet gene therapy needs, Marks says

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

What is microchimerism and how does it affect maternal health?

knowledge

knowledge

explore

focus